Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 187,291 shares, a decrease of 43.3% from the May 31st total of 330,345 shares. Based on an average trading volume of 370,446 shares, the days-to-cover ratio is currently 0.5 days. Approximately 8.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is currently owned by hedge funds and other institutional investors.

Aethlon Medical Stock Performance

Shares of AEMD stock traded down $0.07 during trading hours on Wednesday, hitting $0.76. 230,190 shares of the company were exchanged, compared to its average volume of 339,800. The company has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $2.25. The firm has a market cap of $1.80 million, a P/E ratio of -0.05 and a beta of 1.49. Aethlon Medical has a fifty-two week low of $0.65 and a fifty-two week high of $27.40.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.